Hutchison China MediTech completes patient enrollment in Phase III FALUCA trial
Hutchison China MediTech, or Chi-Med, has completed patient enrollment of FALUCA, its Phase III pivotal trial of fruquintinib in advanced, third-line, non-small cell lung cancer, or NSCLC, patients in China. Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors, or VEGFR, 1, 2 and 3, that has met its primary endpoint in several Phase II and III clinical trials in China for the treatment of lung, colorectal and gastric cancers. Top-line FALUCA data is expected to be reported in late 2018 when the overall survival data is mature and, subject to a positive outcome, would be followed by a second New Drug Application submission thereafter. Fruquintinib's first NDA, for the treatment of colorectal cancer, was submitted to the China Food and Drug Administration, or CFDA, in June 2017.